September 9, 2016 09:42 AM EDT
R&D
News Briefing

Pro­to­cols: No­van down­sizes its IPO; GSK floats idea for gov­ern­ment-backed vac­cine de­vel­op­ment

John Carroll

Editor & Founder

Durham, NC-based No­van has shrunk its am­bi­tions for an up­com­ing IPO. The biotech – which is work­ing on new treat­ments for ac­ne and oth­er skin con­di­tions …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

A service from the Financial Times